Cargando…
Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report
ROS1 tyrosine kinase inhibitors (TKIs) were found to provide a substantial clinical benefit for patients with advanced ROS1-positive (ROS1+) NSCLC. Nevertheless, TKI resistance inevitably develops with different mechanisms, preventing prolonged responses. For this reason, next-generation compounds a...
Autores principales: | Pizzutilo, Elio Gregory, Agostara, Alberto Giuseppe, Roazzi, Laura, Romanò, Rebecca, Motta, Valentina, Lauricella, Calogero, Marrapese, Giovanna, Cerea, Giulio, Signorelli, Diego, Veronese, Silvio Marco, Giannetta, Laura Giuseppina, Sartore-Bianchi, Andrea, Siena, Salvatore |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689265/ https://www.ncbi.nlm.nih.gov/pubmed/38047274 http://dx.doi.org/10.1016/j.jtocrr.2023.100555 |
Ejemplares similares
-
Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity
por: Pizzutilo, Elio Gregory, et al.
Publicado: (2023) -
Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis
por: Pizzutilo, Elio Gregory, et al.
Publicado: (2021) -
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
por: Amatu, Alessio, et al.
Publicado: (2015) -
Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2017) -
Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells
por: Cervantes-Madrid, Diana, et al.
Publicado: (2019)